Skip to main content

Table 3 Changes of ADMA concentration in cardiac tissues

From: Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats

Variables Sham Control Low-dose High-dose
Pre-medical treatment (8 weeks of model production, n = 5 each group)
ADMA (μmol/mg protein) 35.15 ± 6.03* 48.53 ± 8.08 50.44 ± 10.52 49.67 ± 7.33
Post-medical treatment (4 weeks of medical treatment, n = 10 each group)
ADMA (μmol/mg protein) 36.08 ± 7.43* 51.51 ± 8.26 47.26 ± 8.27 41.50 ± 7.08#
  1. Denote: *P < 0.05 versus other groups, #P < 0.05 versus control group.